Press releases
* (R) = Regulatory press releases
Jan 13, 2023
(R) Cantargia successfully concludes toxicity study with CAN10 antibody ahead of phase I clinical trial application
Nov 7, 2022
(R) Cantargia presents new data at SITC 2022 supporting nadunolimab’s promising antitumor clinical efficacy
Oct 28, 2022
Invitation to presentation of Cantargia’s report for the third quarter of 2022 on November 10 at 3.00 p.m. CET
Oct 14, 2022
(R) Cantargia reaches recruitment milestone and focuses nadunolimab development on upcoming randomized studies
Sep 22, 2022
